Abstract
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disease with worldwide increasing incidence. PD is the second most prevalent neurodegenerative disease and the first that involves motor symptoms. The great majority of cases, defined as sporadic with non-familial disease, show a highly variable risk of disease due to environmental and genetic factors that remain largely unknown. Furthermore, the neurodegenerative process typically initiates decades prior to the appearance of hallmark motor symptoms; therefore, clinical diagnosis is enabled only when most of the relevant neurons have died and current treatment is palliative at best. Here, we review the application of genomic scale microarray based research aimed to enable early diagnosis and identify novel targets for therapeutic intervention. We demonstrate that blood leukocytes can serve as a feasible and reliable tissue source to test for diseaseinduced and treatment-related transcript changes. We cover our reports of transcription and alternative splicing modifications in PD patient's leukocytes based on 3’ and exon microarray analyses and the identified inflammatory modulations. We further describe the effects of deep brain stimulation (DBS) neurosurgery on the leukocyte transcripts as reflecting the patient's neurological status. A focus is gained on common genes identified both in the molecular signature of human PD leukocytes and in brain RNA from engineered PD mouse models subjected to risk and protection manipulations. Finally, we discuss potential future directions of high-throughput RNA research as facilitators of the PD knowledge base through next generation sequencing technologies of both long and short RNA transcripts including microRNAs.
Keywords: Alternative splicing, blood leukocytes, deep brain stimulation, early diagnosis, microarrays, MicroRNAs, molecular signature, mouse models, Parkinson’s disease, RNA-Seq.
CNS & Neurological Disorders - Drug Targets
Title:Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
Volume: 12 Issue: 8
Author(s): Lilach Soreq, Hagai Bergman, Zvi Israel and Hermona Soreq
Affiliation:
Keywords: Alternative splicing, blood leukocytes, deep brain stimulation, early diagnosis, microarrays, MicroRNAs, molecular signature, mouse models, Parkinson’s disease, RNA-Seq.
Abstract: Parkinson's disease (PD) is a chronic and progressive neurodegenerative disease with worldwide increasing incidence. PD is the second most prevalent neurodegenerative disease and the first that involves motor symptoms. The great majority of cases, defined as sporadic with non-familial disease, show a highly variable risk of disease due to environmental and genetic factors that remain largely unknown. Furthermore, the neurodegenerative process typically initiates decades prior to the appearance of hallmark motor symptoms; therefore, clinical diagnosis is enabled only when most of the relevant neurons have died and current treatment is palliative at best. Here, we review the application of genomic scale microarray based research aimed to enable early diagnosis and identify novel targets for therapeutic intervention. We demonstrate that blood leukocytes can serve as a feasible and reliable tissue source to test for diseaseinduced and treatment-related transcript changes. We cover our reports of transcription and alternative splicing modifications in PD patient's leukocytes based on 3’ and exon microarray analyses and the identified inflammatory modulations. We further describe the effects of deep brain stimulation (DBS) neurosurgery on the leukocyte transcripts as reflecting the patient's neurological status. A focus is gained on common genes identified both in the molecular signature of human PD leukocytes and in brain RNA from engineered PD mouse models subjected to risk and protection manipulations. Finally, we discuss potential future directions of high-throughput RNA research as facilitators of the PD knowledge base through next generation sequencing technologies of both long and short RNA transcripts including microRNAs.
Export Options
About this article
Cite this article as:
Soreq Lilach, Bergman Hagai, Israel Zvi and Soreq Hermona, Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/187152731131200119
DOI https://dx.doi.org/10.2174/187152731131200119 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Clinical Aspects of Melatonin Intervention in Alzheimers Disease Progression
Current Neuropharmacology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy
Current Pharmaceutical Design 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Exploring Sterol and Lipid Biology in the Functional Genomic Era
Current Pharmaceutical Biotechnology Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence
Current Pharmaceutical Design Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects
Drug Delivery Letters Rapid Regulation of Pancreatic α- and β- Cell Signalling Systems by Estrogens
Infectious Disorders - Drug Targets Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient
CNS & Neurological Disorders - Drug Targets MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Novel Treatments of Schizophrenia: Targeting the Neurotensin System
CNS & Neurological Disorders - Drug Targets Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Synaptic Inputs of Neural Afferent Pathways to Vasopressin- and Oxytocin-Secreting Neurons of Supraoptic and Paraventricular Hypothalamic Nuclei
Endocrine, Metabolic & Immune Disorders - Drug Targets Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism